Download
00406_2024_Article_1911.pdf 1,65MB
WeightNameValue
1000 Titel
  • Is there a rationale for hyperbaric oxygen therapy in the patients with Post COVID syndrome? : A critical review
1000 Autor/in
  1. Pawlik, Michael |
  2. Rinneberg, G |
  3. Koch, A |
  4. Meyringer, H |
  5. Loew, TH |
  6. Kjellberg, A |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-11-15
1000 Erschienen in
1000 Quellenangabe
  • 274(8):1797-1817
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00406-024-01911-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579208/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>The SARS-CoV-2 pandemic has resulted in 762 million infections worldwide from 2020 to date, of which approximately ten percent are suffering from the effects after infection in 2019 (COVID-19) [1, 40]. In Germany, it is now assumed that at least one million people suffer from post-COVID condition with long-term consequences. These have been previously reported in diseases like Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS). Symptoms show a changing variability and recent surveys in the COVID context indicate that 10–30 % of outpatients, 50 to 70% of hospitalised patients suffer from sequelae. Recent data suggest that only 13% of all ill people were completely free of symptoms after recovery [3, 9]. Current hypotheses consider chronic inflammation, mitochondrial dysfunction, latent viral persistence, autoimmunity, changes of the human microbiome or multilocular sequelae in various organ system after infection. Hyperbaric oxygen therapy (HBOT) is applied since 1957 for heart surgery, scuba dive accidents, CO intoxication, air embolisms and infections with anaerobic pathogens. Under hyperbaric pressure, oxygen is physically dissolved in the blood in higher concentrations and reaches levels four times higher than under normobaric oxygen application. Moreover, the alternation of hyperoxia and normoxia induces a variety of processes at the cellular level, which improves oxygen supply in areas of locoregional hypoxia. Numerous target gene effects on new vessel formation, anti-inflammatory and anti-oedematous effects have been demonstrated [74]. The provision of intermittently high, local oxygen concentrations increases repair and regeneration processes and normalises the predominance of hyperinflammation. At present time only one prospective, randomized and placebo-controlled study exists with positive effects on global cognitive function, attention and executive function, psychiatric symptoms and pain interference. In conclusion, up to this date HBO is the only scientifically proven treatment in a prospective randomized controlled trial to be effective for cognitive improvement, regeneration of brain network and improvement of cardiac function. HBOT may have not only theoretical but also potential impact on targets of current pathophysiology of Post COVID condition, which warrants further scientific studies in patients.</jats:p>
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Invited Review
lokal Humans [MeSH]
lokal Post COVID condition
lokal COVID-19
lokal Post-Acute COVID-19 Syndrome [MeSH]
lokal COVID-19/complications [MeSH]
lokal COVID-19/therapy [MeSH]
lokal Chronic fatigue syndrome
lokal Brain fog
lokal Long COVID
lokal SARS-CoV-2 [MeSH]
lokal Hyperbaric Oxygenation/methods [MeSH]
lokal Hyperbaric oxygen therapy (HBOT)
lokal Hypoxia-inducible-factor-1
lokal SARS-CoV-2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-4594-4841|https://frl.publisso.de/adhoc/uri/UmlubmViZXJnLCBH|https://frl.publisso.de/adhoc/uri/S29jaCwgQQ==|https://frl.publisso.de/adhoc/uri/TWV5cmluZ2VyLCBI|https://frl.publisso.de/adhoc/uri/TG9ldywgVEg=|https://frl.publisso.de/adhoc/uri/S2plbGxiZXJnLCBB
1000 Hinweis
  • DeepGreen-ID: c724676b276949349e3482a4ed8c562d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universität Regensburg |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universität Regensburg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6495072.rdf
1000 Erstellt am 2025-02-04T06:36:18.919+0100
1000 Erstellt von 322
1000 beschreibt frl:6495072
1000 Zuletzt bearbeitet 2025-09-14T12:57:38.308+0200
1000 Objekt bearb. Sun Sep 14 12:57:38 CEST 2025
1000 Vgl. frl:6495072
1000 Oai Id
  1. oai:frl.publisso.de:frl:6495072 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source